Aytu BioPharma, Inc. (AYTU)

Market Cap	22.62M
Revenue (ttm)	63.70M
Net Income (ttm)	-13.07M
Shares Out	10.19M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,713
Open	2.220
Previous Close	2.240
Day's Range	2.180 - 2.243
52-Week Range	0.950 - 2.820
Beta	0.29
Analysts	Strong Buy
Price Target	9.17 (+313.06%)
Earnings Date	Nov 13, 2025

About AYTU

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Joshua Disbrow
• Employees: 83
• Stock Exchange: NASDAQ
• Ticker Symbol: AYTU
• Website: https://aytubio.com

Financial Performance

In 2025, Aytu BioPharma's revenue was $66.38 million, an increase of 1.84% compared to the previous year's $65.18 million. Losses were -$13.56 million, -14.40% less than in 2024.

Analyst Forecast

According to 3 analysts, the average rating for AYTU stock is "Strong Buy." The 12-month stock price target is $9.17, which is an increase of 313.06% from the latest price.

Price Target

$9.17

(313.06% upside)

Analyst Consensus: Strong Buy